ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
A Magnetically Driven Amoeba-Like Nanorobot for Whole-Process Active Drug Transport.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Magnetic nanorobots in oncology: From targeted drug delivery to smart theranostic systems.Materials today. Bio · 2026Review
- Amphibious Movement of Microrobots Inspired by Water Spiders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Application of Micro/Nanorobots in Cancer Therapy.Micromachines · 2026Review
- The Future of Breast Cancer Treatment: From Conventional Wisdom to Nanotechnology-Enabled Precision.International journal of molecular sciences · 2026Review
- Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Nanorobotics in cancer care: innovation without translation?Annals of medicine and surgery (2012) · 2026Article
- Therapeutic applications of nanobots and nanocarriers in cancer treatment.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- γ-glutamyl transpeptidase-catalyzed polymer-enzyme-drug conjugate enhances penetration and suppression in oral squamous cell carcinoma via transdermal application.Materials today. Bio · 2025Article
- Deformable nanocarriers for enhanced drug delivery and cancer therapy.Exploration (Beijing, China) · 2024Review
- Magnetic Cellular Backpacks for Spatial Targeting, Imaging, and Immunotherapy.ACS applied bio materials · 2024Review
- An Intrinsically Magnetic Epicardial Patch for Rapid Vascular Reconstruction and Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases.Drug delivery · 2023Review
- A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy.Bioactive materials · 2023Article
- Advances of medical nanorobots for future cancer treatments.Journal of hematology & oncology · 2023Review
- A Magnetically Driven Amoeba-Like Nanorobot for Whole-Process Active Drug Transport.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The passive diffusion performance of nanocarriers results in inefficient drug transport across multiple biological barriers and consequently cancer therapy failure. Here, a magnetically driven amoeba-like nanorobot (amNR) is presented for whole-process active drug transport. The amNR is actively extravasated from blood vessels and penetrated into deep tumor tissue through a magnetically driven deformation effect. Moreover, the acidic microenvironment of deep tumor tissue uncovers the masked targeting ligand of amNR to achieve active tumor cell uptake. Furthermore, the amNR rapidly releases the encapsulated doxorubicin (DOX) after alternating magnetic field application. The amNRs eventually deliver DOX into ≈92.3% of tumor cells and completely delay tumor growth with an inhibition rate of 96.1%. The deformable amNRs, with the assistance of magnetic field application, provide a facile strategy for whole-process active drug transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.